Division of Clinical Pharmacology, Department of Medicine, Division of Cardiology, Department of Medicine, Department of Biomedical Engineering and Physics, and Division of Cardiology, Department of Pediatrics, Vanderbilt University, Nashville, TN; and Department of Cardiovascular Diseases, University of Pisa, Pisa, Italy.
Circ Arrhythm Electrophysiol. 2014 Apr;7(2):313-20. doi: 10.1161/CIRCEP.113.000994. Epub 2014 Feb 3.
Atrial fibrillation (AF) risk has been associated with leaky ryanodine receptor 2 (RyR2) Ca release channels. Patients with mutations in RyR2 or in the sarcoplasmic reticulum Ca-binding protein calsequestrin 2 (Casq2) display an increased risk for AF. Here, we examine the underlying mechanisms of AF associated with loss of Casq2 and test mechanism-based drug therapy.
Compared with wild-type Casq2+/+ mice, atrial burst pacing consistently induced atrial flutter or AF in Casq2-/- mice and in isolated Casq2-/- hearts. Atrial optical voltage maps obtained from isolated hearts revealed multiple independent activation sites arising predominantly from the pulmonary vein region. Ca and voltage mapping demonstrated diastolic subthreshold spontaneous Ca elevations (SCaEs) and delayed afterdepolarizations whenever the pacing train failed to induce AF. The dual RyR2 and Na channel inhibitor R-propafenone (3 μmol/L) significantly reduced frequency and amplitude of SCaEs and delayed afterdepolarizations in atrial myocytes and intact atria and prevented induction of AF. In contrast, the S-enantiomer of propafenone, an equipotent Na channel blocker but much weaker RyR2 inhibitor, did not reduce SCaEs and delayed afterdepolarizations and failed to prevent AF.
Loss of Casq2 increases risk of AF by promoting regional SCaEs and delayed afterdepolarizations in atrial tissue, which can be prevented by RyR2 inhibition with R-propafenone. Targeting AF caused by leaky RyR2 Ca channels with R-propafenone may be a more mechanism-based approach to treating this common arrhythmia.
心房颤动 (AF) 的风险与兰尼碱受体 2 (RyR2) 钙释放通道的渗漏有关。RyR2 或肌质网 Ca 结合蛋白 calsequestrin 2 (Casq2) 突变的患者发生 AF 的风险增加。在这里,我们研究了与 Casq2 缺失相关的 AF 的潜在机制,并测试了基于机制的药物治疗。
与野生型 Casq2+/+ 小鼠相比,心房爆发起搏一致地在 Casq2-/- 小鼠和分离的 Casq2-/- 心脏中诱导心房扑动或 AF。从分离的心脏获得的心房光学电压图显示,多个独立的激活点主要来自肺静脉区域。Ca 和电压图显示,每当起搏训练未能诱导 AF 时,舒张亚阈值自发性 Ca 升高 (SCaEs) 和延迟后除极就会出现。双重 RyR2 和 Na 通道抑制剂 R-丙吡胺 (3 μmol/L) 显著降低了心房肌细胞和完整心房中 SCaEs 和延迟后除极的频率和幅度,并防止了 AF 的诱导。相比之下,丙吡胺的 S-对映体,一种等效的 Na 通道阻断剂,但 RyR2 抑制剂较弱,不能降低 SCaEs 和延迟后除极,也不能防止 AF。
Casq2 的缺失通过促进心房组织中的区域性 SCaEs 和延迟后除极来增加 AF 的风险,这可以通过 RyR2 抑制用 R-丙吡胺来预防。用 R-丙吡胺靶向 RyR2 钙通道泄漏引起的 AF 可能是治疗这种常见心律失常的更基于机制的方法。